News | May 19, 2022
WHO validates Convidecia vaccine for Covid-19
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
This cost-effective tool will be of immense benefit to other high burden countries as well.
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
WHO and UNICEF call on governments, industry, donors and civil society to fund and prioritize access to assistive products
“We are committed to making India a global medical value hub by further strengthening our traditional medicine industry and boosting 'Heal in India' & 'Heal by India'
HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy's will handle local clinical development, registration, marketing and sales
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
RNA extraction free kit to deliver results in just 45 minutes
The renewed commitment will provide continued preventative (prophylactic) treatment to as many as 1,000 people with haemophilia A in locations where there is little to no access to haemophilia treatment
Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases
Subscribe To Our Newsletter & Stay Updated
